DPP‐4/SGLT2 inhibitor combined therapy for type 2 diabetes
Sign Up to like & getrecommendations! Published in 2017 at "Prescriber"
DOI: 10.1002/psb.1626
Abstract: DPP‐4 inhibitors and SGLT2 inhibitors lower blood glucose by complementary mechanisms of action, and two fixed‐dose combinations – Qtern and Glyxambi – have now been approved for the treatment of type 2 diabetes. This article… read more here.
Keywords: inhibitor combined; dpp sglt2; sglt2 inhibitor; combined therapy ... See more keywords